Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126709 | 0.75 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL3144063 | 0.73 | SOAT1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16048128 | 0.73 | ALDH1A1 (0.37) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1513788 | 0.72 | — | — | |
| SCHEMBL7614203 | 0.72 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16049142 | 0.72 | ALDH1A1 (0.36) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL1778910 | 0.71 | ALDH1A1 (0.39) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL18446 | 0.71 | ALDH1A1 (0.53) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL23234042 | 0.68 | — | — | |
| SCHEMBL2945943 | 0.68 | GAA (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1851214-B1 | ISOXAZOLINE DERIVATIVE AND NOVEL PROCESS FOR ITS PREPARATION | LG LIFE SCIENCES LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-8044080-B2 | Isoxazoline derivative and novel process for its preparation | LG LIFE SCIENCES LTD. (KR) | 2011-10-25 | — | — | US | disclosed |
| US-20100160370-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010005766-A1 | USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING A CASPASE INHIBITOR FOR TREATING INTERSTITIAL LUNG DISEASES | GILEAD SCIENCES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20100008867-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2010005765-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20080262032-A1 | Isoxazoline Derivative and Novel Process for Its Preparation | LG CHEM, LTD. (KR) | 2008-10-23 | — | — | US | disclosed |
| EP-1851214-A1 | ISOXAZOLINE DERIVATIVE AND NOVEL PROCESS FOR ITS PREPARATION | LG Life Sciences Ltd. (KR) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006090997-A1 | ISOXAZOLINE DERIVATIVE AND NOVEL PROCESS FOR ITS PREPARATION | LG LIFE SCIENCES LTD. (KR) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262032-A1 | Isoxazoline Derivative and Novel Process for Its Preparation | CASP7, CASP1, CASP14 | ALDH1A1 1201/4885LMNA 609/4885HSD17B10 236/4885 |
| US-20100160370-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS | CASP3, CASP5, CASP2 | ALDH1A1 2415/4885LMNA 308/4885HSD17B10 1151/4885 |
| US-20100008867-A1 | METHOD OF TREATMENT AND PHARMACEUTICAL COMPOSITIONS | CASP3, CASP5, CASP2 | ALDH1A1 2415/4885LMNA 308/4885HSD17B10 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.